News Sentiment

WST sentiment intelligence

West Pharmaceutical Services Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 31 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Medical Instruments & Supplies Read-through group
Latest close 353.71 Week of 10 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

73/100 classification confidence.

Company focus 31

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-3.3% over one week, +7.6% over four weeks, trend active, and near fair-value range.

Latest direct headline Positive

TD Cowen Adjusts Price Target on West Pharmaceutical Services to $410 From $365, Maintains Buy Rating

Market Reaction

Balanced read

64/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 73/100 classification
One-week reaction -3.3% Price reacting lower
Trend fit Trend active 7.6% over four weeks
Fair value 17.3% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 16
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 31
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Market source 8
Ad Hoc News 5
TradingView 4
Stock Titan 3
Sahm 2
simplywall.st 2
MT Newswires 1
Simply Wall Street 1

Event Lens

What the news is about

Classified themes
Market update 11
Earnings 7
Analyst action 6
Macro sensitivity 5
Regulatory and legal 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 31
TradingView Direct company coverage

Reasons to Add West Pharmaceutical Stock to Your Portfolio Now

West Pharmaceutical Services (WST) is a strong candidate for investment due to robust demand for its High-Value Products, the expansion of GLP-1 drug programs, and regulatory changes like Annex 1 conversions. While the company faces challenges such as concentration risk from GLP-

Tone
Positive 72/100
Event
Regulatory and legal
Published
15 Jul 2026 16:10
Source
TradingView
Stock Titan Direct company coverage

West Pharmaceutical (NYSE: WST) inks 10-year Daikyo licensing, distribution deal

West Pharmaceutical Services Inc. has signed new 10-year technology exchange and distributorship agreements with Daikyo Seiko, Ltd., effective July 14, 2026. These agreements facilitate mutual sharing of know-how, patents, and trademarks for pharmaceutical packaging components, w

Tone
Positive 64/100
Event
Deals and strategy
Published
14 Jul 2026 20:30
Source
Stock Titan
TradingView Direct company coverage

Zacks Industry Outlook McKesson, Cardinal, West Pharmaceutical, Align and Henry

The medical supply industry is experiencing strong tailwinds in the second half of 2026, driven by resilient healthcare utilization, rising specialty care demand, and the adoption of digital technologies. Companies like McKesson, Cardinal Health, West Pharmaceutical Services, Ali

Tone
Positive 73/100
Event
Macro sensitivity
Published
14 Jul 2026 07:39
Source
TradingView
Simply Wall Street Direct company coverage

WST: GLP 1 Injectables And On Body Delivery Moves Will Shape Future Returns

Analysts have raised the target price for West Pharmaceutical Services (WST) to $379.00, citing strong sector trends, exposure to GLP-1 related volumes, and positive analyst ratings. The company recently reported robust Q1 2026 revenues, raised full-year guidance, and continues t

Tone
Positive 67/100
Event
Analyst action
Published
13 Jul 2026 21:10
Source
Simply Wall Street
Moomoo Direct company coverage

BNP Paribas Initiates West Pharmaceutical Services at Outperform With $447 Price Target

BNP Paribas has initiated coverage of West Pharmaceutical Services (NYSE:WST) with an Outperform rating. The firm has set a price target of $447 for the company's stock, indicating a positive outlook for its future performance. This initiation by BNP Paribas suggests confidence i

Tone
Positive 67/100
Event
Analyst action
Published
13 Jul 2026 18:11
Source
Moomoo
TradingView Direct company coverage

West Pharmaceutical Services, Inc. Stock 12‑Month Price Target Raised to $383.93, Implies 9% Upside

The average 12-month price target for West Pharmaceutical Services, Inc. (WST) stock has been raised to $383.93 from $380.36 by 14 analysts, with forecasts ranging from $340 to $447. This updated target suggests a potential 9% upside from its closing price on July 10. The consens

Tone
Positive 70/100
Event
Analyst action
Published
13 Jul 2026 16:20
Source
TradingView
TradingView Direct company coverage

West Pharmaceutical Services, Inc. Stock 12‑Month Price Target Raised to $374.08, Implies 6% Upside

The average 12-month price target for West Pharmaceutical Services, Inc. (WST) stock has been raised from $370.23 to $374.08 by 13 analysts, with forecasts ranging from $340 to $410 per share. This new target implies approximately 6% potential upside from the July 10 closing pric

Tone
Positive 73/100
Event
Analyst action
Published
13 Jul 2026 13:20
Source
TradingView
Sahm Direct company coverage

West Pharmaceutical Services (WST) Sells SmartDose Rights, Is The Stock Fully Priced?

West Pharmaceutical Services (WST) has sold the manufacturing and supply rights for its SmartDose 3.5mL On Body Delivery System to AbbVie, shifting focus to its core drug delivery business. Despite strong short-term stock performance, the company's valuation presents a mixed pict

Tone
Neutral 50/100
Event
Macro sensitivity
Published
12 Jul 2026 04:09
Source
Sahm
Sahm Direct company coverage

The Bull Case For West Pharmaceutical Services (WST) Could Change Following Its Q1 2026 Earnings Beat And Upgrades - Learn Why

West Pharmaceutical Services (WST) recently reported strong first-quarter 2026 earnings and revenue, surpassing industry benchmarks and leading to increasingly positive analyst estimate revisions. This performance reinforces optimism around the company's outlook, tied closely to

Tone
Neutral 50/100
Event
Earnings
Published
10 Jul 2026 22:09
Source
Sahm
Market source Direct company coverage

West Pharmaceutical Services (WST) Sells SmartDose Rights To AbbVie To Refocus Its Business

West Pharmaceutical Services (WST) has sold the rights and facilities for its SmartDose 3.5 mL On Body Delivery System to AbbVie, aiming to refocus its business on other high-value drug delivery platforms. This move allows West to concentrate on larger volume on-body delivery sol

Tone
Positive 64/100
Event
Market update
Published
10 Jul 2026 19:12
Source
Market source
MarketWatch Direct company coverage

West Pharmaceutical Services Inc. stock underperforms Friday when compared to competitors

West Pharmaceutical Services Inc. (WST) stock fell 1.10% on Friday, closing at $353.71, even as the broader market saw gains with the S&P 500 Index rising 0.42% and the Dow Jones Industrial Average up 0.29%. The company's stock is now 3.79% below its 52-week high of $367.66 set o

Tone
Negative 29/100
Event
Market update
Published
10 Jul 2026 17:02
Source
MarketWatch